Technical analysis of Genprex, Inc. (GNPX): price and volume charts, candlestick patterns, moving averages (SMA, EMA), RSI, MACD, ADX and Bollinger Bands. Identify momentum, trend direction and potential entry/exit zones.
Genprex, Inc. is a biotechnology firm specializing in gene therapy, with its primary focus on advancing treatments through clinical stages. Their mission revolves around developing innovative therapies for patients battling cancer and diabetes. Leading their product pipeline is REQORSA (GPX-001), a flagship gene therapy candidate specifically designed to target both non-small cell lung cancer and small cell lung cancer.
Price Performance
| 1 month | -13.67% |
| 3 months | -73.81% |
| Year-to-date | -91.14% |
| 1 year | -98.67% |
| 3 years | -99.98% |
| 5 years | -100.00% |
52-Week Range
| 52-week High | $1210.00 |
| 52-week Low | $3.26 |
| Avg Volume (90d) | 126K |
Technical Indicators
| SMA 50 | $5.71 |
| SMA 200 | $28.59 |
| 30-day Volatility (annualised) | 69.1% |
| Price vs SMA 50 | -40.2% |
| Price vs SMA 200 | -88.1% |
Monthly Close (12 months)
| Month | Close | Change |
|---|
| 2025-10 | $126.94 | |
| 2025-11 | $65.12 | -48.7% |
| 2025-12 | $38.50 | -40.9% |
| 2026-01 | $58.52 | +52.0% |
| 2026-02 | $44.00 | -24.8% |
| 2026-03 | $39.82 | -9.5% |
| 2026-04 | $21.45 | -46.1% |
| 2026-05 | $17.15 | -20.0% |
| 2026-06 | $11.42 | -33.4% |
| 2026-07 | $5.99 | -47.5% |
| 2026-08 | $3.71 | -38.1% |
| 2026-09 | $3.41 | -8.1% |
Upcoming Earnings
| Date | EPS Est. | Revenue Est. |
|---|
| 2026-09-14 | $-2.53 | |
| 2026-09-14 | $-0.05 | $8M |
| 2026-09-14 | $0.06 | $3M |
| 2026-09-14 | | |
| 2026-09-14 | $0.12 | $7M |
| 2026-09-14 | | |
Price
| Price | $3.41 |
| Market Cap | $2M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 0.10 |
| EV / EBITDA | 0.85 |
| Dividend Yield | 0.00% |
Financial Health
| Debt / Equity | 0.00 |
| Current Ratio | 6.77 |
| Piotroski F-Score | 3 |
| Altman Z-Score | -27.43 |